DiaMedica Therapeutics Inc (DMA):企業の財務・戦略的SWOT分析

◆英語タイトル:DiaMedica Therapeutics Inc (DMA) - Financial and Strategic SWOT Analysis Review
◆商品コード:DATA904C14987
◆発行会社(調査会社):GlobalData
◆発行日:2019年3月
◆ページ数:25
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD300 ⇒換算¥33,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD600 ⇒換算¥66,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD900 ⇒換算¥99,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
DiaMedica Therapeutics Inc (DiaMedica), formerly DiaMedica Inc is a clinical-stage biopharmaceutical company which develops innovative medicines for the treatment neurological and kidney diseases. Its lead product candidate DM-199, is a human recombinant protein that treats diabetes type 1 and type 2, and associated complications including diabetic kidney disease and alport syndrome; and DM300 for treating acute pancreatitis. DiaMedica’s DM199 is also used for the treatment of diabetic nephropathy and post-insult treatment from acute ischemic stroke (AIS). The company discovers and develops novel therapies for kidney dysfunction and metabolic disorders. The company also provides clinical trial services. DiaMedica is headquartered in Minneapolis, Minnesota, the US.

DiaMedica Therapeutics Inc Key Recent Developments

Jan 09,2019: Diamedica Therapeutics announces voluntary delisting from TSX Venture Exchange
Sep 05,2018: DiaMedica Therapeutics Announces the Appointment of Dr. Harry Alcorn Jr. as Chief Medical Officer[Newswire : Healthcare - GNW RSS]
Apr 05,2018: DiaMedica Therapeutics Announces Appointment of Scott Kellen as Chief Financial Officer
Jan 18,2018: DiaMedica Letter to Shareholders

This comprehensive SWOT profile of DiaMedica Therapeutics Inc provides you an in-depth strategic analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

This company report forms part of GlobalData’s ‘Profile on Demand’ service, covering over 50,000 of the world’s leading companies. Once purchased, GlobalData’s highly qualified team of company analysts will comprehensively research and author a full financial and strategic analysis of DiaMedica Therapeutics Inc including a detailed SWOT analysis, and deliver this direct to you in pdf format within two business days. (excluding weekends).

The profile contains critical company information including*,

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note*: Some sections may be missing if data is unavailable for the company.

Key benefits of buying this profile include,

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

【レポートの目次】

Table of Contents

Section 1 – About the Company

DiaMedica Therapeutics Inc – Key Information
DiaMedica Therapeutics Inc – Overview
DiaMedica Therapeutics Inc – Key Employees
DiaMedica Therapeutics Inc – Key Employee Biographies
DiaMedica Therapeutics Inc – Key Operational Heads
DiaMedica Therapeutics Inc – Major Products and Services
DiaMedica Therapeutics Inc – History
DiaMedica Therapeutics Inc – Company Statement
DiaMedica Therapeutics Inc – Locations And Subsidiaries
DiaMedica Therapeutics Inc – Key Manufacturing facilities
Head Office
Other Locations & Subsidiaries

Section 2 – Company Analysis

DiaMedica Therapeutics Inc – Business Description
DiaMedica Therapeutics Inc – Corporate Strategy
DiaMedica Therapeutics Inc – SWOT Analysis
SWOT Analysis – Overview
DiaMedica Therapeutics Inc – Strengths
DiaMedica Therapeutics Inc – Weaknesses
DiaMedica Therapeutics Inc – Opportunities
DiaMedica Therapeutics Inc – Threats
DiaMedica Therapeutics Inc – Key Competitors

Section 3 – Company Financial Performance Charts

DiaMedica Therapeutics Inc – Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts

Section 4 – Appendix

Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

Note*: Some sections may be missing if data is unavailable for the company

List of Tables

DiaMedica Therapeutics Inc, Key Information
DiaMedica Therapeutics Inc, Key Ratios
DiaMedica Therapeutics Inc, Share Data
DiaMedica Therapeutics Inc, Major Products and Services
DiaMedica Therapeutics Inc, History
DiaMedica Therapeutics Inc, Key Employees
DiaMedica Therapeutics Inc, Key Employee Biographies
DiaMedica Therapeutics Inc, Key Operational Heads
DiaMedica Therapeutics Inc, Other Locations
DiaMedica Therapeutics Inc, Subsidiaries
DiaMedica Therapeutics Inc, Key Manufacturing facilities
DiaMedica Therapeutics Inc, Key Competitors
DiaMedica Therapeutics Inc, SWOT Analysis
DiaMedica Therapeutics Inc, Ratios based on current share price
DiaMedica Therapeutics Inc, Annual Ratios
DiaMedica Therapeutics Inc, Interim Ratios
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures

DiaMedica Therapeutics Inc, Performance Chart
DiaMedica Therapeutics Inc, Ratio Charts

★海外企業調査レポート[DiaMedica Therapeutics Inc (DMA):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Valvoline Inc (VVV):企業の財務・戦略的SWOT分析
    Valvoline Inc (VVV) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • AMETEK Inc (AME):医療機器:M&Aディール及び事業提携情報
    Summary AMETEK Inc (AMETEK) is an electronic products manufacturing company that manufactures electronic instruments and electromechanical devices. The company's products include medical materials, motion control systems, sub assemblies and connectors, electrical cord reels, gauges, titanium alloys …
  • EIH Limited:戦略・SWOT・企業財務分析
    EIH Limited - Strategy, SWOT and Corporate Finance Report Summary EIH Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • North Energy ASA (NORTH):企業の財務・戦略的SWOT分析
    Summary North Energy ASA (North Energy) is an upstream oil and gas company that provides exploration and development services in Norwegian Continental Shelf (NCS). The company’s services include oil and gas exploration and development, license mapping and drilling programs, and conducting geological …
  • Micell Technologies Inc:製品パイプライン分析
    Summary Micell Technologies Inc (Micell) is a medical device company that develops drug delivery systems for the treatment of cardiovascular diseases. The company offers product such as MiStent sirolimus eluting absorbable polymer coronary stent system, a drug-eluting stent that is designed to optim …
  • Capita plc:企業の戦略・SWOT・財務情報
    Capita plc - Strategy, SWOT and Corporate Finance Report Summary Capita plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • JetBlue Airways Corp:企業の戦略・SWOT・財務分析
    JetBlue Airways Corp - Strategy, SWOT and Corporate Finance Report Summary JetBlue Airways Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Linklaters Llp
    Linklaters Llp - Strategy, SWOT and Corporate Finance Report Summary Linklaters Llp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • TESARO Inc (TSRO):製薬・医療:M&Aディール及び事業提携情報
    Summary TESARO Inc (TESARO) is an oncology-focused biopharmaceutical company that focuses on developing in-licensed, oncology-related product candidates and discovery of new candidates. It develops products using different approaches, comprising small molecules and immuno-oncology antibodies. The co …
  • Auris Medical Holding AG (EARS):製薬・医療:M&Aディール及び事業提携情報
    Summary Auris Medical Holding AG (Auris Medical) is a clinical-stage biopharmaceutical company with focus on neurotology and mental health supportive care. The company’s pipeline product candidates are in various clinical phases intended for the treatment of acute inner ear tinnitus, post-acute inne …
  • Libbey Inc (LBY):企業の財務・戦略的SWOT分析
    Libbey Inc (LBY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Cellular Biomedicine Group Inc (CBMG):企業の財務・戦略的SWOT分析
    Summary Cellular Biomedicine Group Inc (CBMG) is a clinical stage biopharmaceutical firm that develops biomedicine, immunotherapy products for cancer and stem cell therapies to address patient specific medical conditions. The firm’s products comprise clinical treatment protocols for the treatment of …
  • Myelin Repair Foundation:製薬・医療:M&Aディール及び事業提携情報
    Summary Myelin Repair Foundation (MRF) is a medical research organization that discovers and develops myelin repair therapeutics for multiple sclerosis. The organization publishes various peer-reviewed scientific articles, identifies different myelin repair treatment targets and discovers multiple r …
  • St. George Bank Limited:企業の戦略・SWOT・財務情報
    St. George Bank Limited - Strategy, SWOT and Corporate Finance Report Summary St. George Bank Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Saudi Arabian Oil Co:企業の戦略的SWOT分析
    Saudi Arabian Oil Co - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Rohto Pharmaceutical Co Ltd (4527):企業の財務・戦略的SWOT分析
    Rohto Pharmaceutical Co Ltd (4527) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Cardia Inc-医療機器分野:企業M&A・提携分析
    Summary Cardia Inc (Cardia) is a medical device company that designs, manufactures, and markets transcatheter septal occluders for cardiac defect patients. The company’s products include ultrasept ASD, ultraseptLAA, ultraseptPFO, fontan occlude among others. Its UltraseptASD is used for the transven …
  • Gardiner & Theobald LLP:企業の戦略的SWOT分析
    Gardiner & Theobald LLP - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …
  • Semma Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Semma Therapeutics Inc (Semma Therapeutics) is a biotechnology company that develops cell replacement therapy for the treatment of diabetes. The company develops therapies using stem cells of the individuals with Type 1 diabetes to produce their own insulin that will regulate the blood sugar …
  • Somnomed Ltd (SOM):企業の財務・戦略的SWOT分析
    Summary Somnomed Ltd (SomnoMed) is a medical device company that develops, produces, commercializes and markets devices for the oral treatment of sleep-related disorders. The company’s products include Somnodent, an oral appliance for obstructive sleep apnea; and Somnobrux, a mouthguard that protect …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆